FCER1G and myeloid sarcoma: However, lower proportions of FcRγ(–) CD56dim NK cells were found in IFNβ-treated patients as compared to untreated cases (9.6% ± 8.2 vs. 19.3% ± 19.7, p < 0.05), a finding only perceived in CD56dim NK cells from HCMV(+) but not in HCMV(–) MS cases, who displayed low proportions of FcRγ(–) NK cells independently of treatment (Figure 4B).